Citigroup upgrades Bio-Techne to Buy with a new PT of $70.
ByAinvest
Thursday, Aug 21, 2025 8:48 am ET1min read
C--
The upgrade follows a significant increase in Citigroup's stake in Bio-Techne. According to its latest Form 13F filing with the Securities and Exchange Commission, Citigroup boosted its position by 131.1% during the first quarter, acquiring an additional 171,863 shares to total 302,927 shares [2].
Bio-Techne's recent earnings report also demonstrated strong performance. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate by $0.03. Revenue for the quarter was $316.96 million, up 3.6% year-over-year. The company's return on equity was 13.43%, and its net margin was 6.02% [2].
In addition to Citigroup's upgrade, several other analysts have also shown optimism towards Bio-Techne. UBS Group, Stephens, and TD Cowen have all set "buy" ratings with varying price targets, while Royal Bank of Canada has set a "sector perform" rating. Despite these positive ratings, Bio-Techne currently has an average rating of "Moderate Buy" and an average price target of $69.42 [2].
The company's stock has seen a steady increase in recent months, trading up $0.35 during midday trading on Monday, July 2, 2025, to hit $53.95. The stock's fifty-day moving average is $52.72, and its 200-day moving average is $55.17 [2].
Bio-Techne's strong financial performance and positive analyst ratings suggest that the company is well-positioned for future growth. The recent upgrades and increased institutional investment could further drive the stock's performance.
References:
[1] https://www.marketscreener.com/news/analyst-recommendations-coreweave-coty-marvell-snap-amda--ce7c51d3dc8bf327
[2] https://www.marketbeat.com/instant-alerts/filing-citigroup-inc-buys-171863-shares-of-bio-techne-corp-nasdaqtech-2025-08-14/
TECH--
Citigroup upgrades Bio-Techne to Buy with a new PT of $70.
Citigroup has recently upgraded its recommendation for Bio-Techne Corporation (NASDAQ: TECH) to "Buy" and raised the price target to $70. This move comes amidst a series of analyst upgrades and institutional investments in the biotechnology company.The upgrade follows a significant increase in Citigroup's stake in Bio-Techne. According to its latest Form 13F filing with the Securities and Exchange Commission, Citigroup boosted its position by 131.1% during the first quarter, acquiring an additional 171,863 shares to total 302,927 shares [2].
Bio-Techne's recent earnings report also demonstrated strong performance. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate by $0.03. Revenue for the quarter was $316.96 million, up 3.6% year-over-year. The company's return on equity was 13.43%, and its net margin was 6.02% [2].
In addition to Citigroup's upgrade, several other analysts have also shown optimism towards Bio-Techne. UBS Group, Stephens, and TD Cowen have all set "buy" ratings with varying price targets, while Royal Bank of Canada has set a "sector perform" rating. Despite these positive ratings, Bio-Techne currently has an average rating of "Moderate Buy" and an average price target of $69.42 [2].
The company's stock has seen a steady increase in recent months, trading up $0.35 during midday trading on Monday, July 2, 2025, to hit $53.95. The stock's fifty-day moving average is $52.72, and its 200-day moving average is $55.17 [2].
Bio-Techne's strong financial performance and positive analyst ratings suggest that the company is well-positioned for future growth. The recent upgrades and increased institutional investment could further drive the stock's performance.
References:
[1] https://www.marketscreener.com/news/analyst-recommendations-coreweave-coty-marvell-snap-amda--ce7c51d3dc8bf327
[2] https://www.marketbeat.com/instant-alerts/filing-citigroup-inc-buys-171863-shares-of-bio-techne-corp-nasdaqtech-2025-08-14/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet